Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug combinations and interactions with class III agents.

F I Marcus1

  • 1Department of Medicine, University of Arizona Health Sciences Center, Tucson 85724.

Journal of Cardiovascular Pharmacology
|January 1, 1992
PubMed
Summary

Combining antiarrhythmic drugs like sotalol and amiodarone may improve efficacy and manage ventricular tachycardia. Sotalol has minimal drug interactions, while amiodarone

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Familial Mahaim syndrome.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·2001
Same author

Baroreflex sensitivity and heart rate variability in the identification of patients at risk for life-threatening arrhythmias: implications for clinical trials.

Circulation·2001
Same author

Electrocardiographic features of inherited diseases that predispose to the development of cardiac arrhythmias, long QT syndrome, arrhythmogenic right ventricular cardiomyopathy/dysplasia, and Brugada syndrome.

Journal of electrocardiology·2001
Same author

Moving toward a new definition of acute myocardial infarction for the 21st century: status of the ESC/ACC consensus conference. European Society of Cardiology and American College of Cardiology.

Journal of electrocardiology·2001
Same author

Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. European Society of Cardiology and the Scientific Council on Cardiomyopathies of the World Heart Federation.

Journal of cardiovascular electrophysiology·2000
Same author

Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation.

Circulation·2000

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Class III antiarrhythmic agents, including sotalol and amiodarone, are crucial in managing cardiac arrhythmias.
  • Systematic studies on drug combinations involving these agents are limited.
  • Existing data suggest potential benefits of combining specific antiarrhythmics.

Purpose of the Study:

  • To review and synthesize current knowledge on drug combinations involving class III antiarrhythmic agents.
  • To explore the efficacy and pharmacokinetic profiles of combined antiarrhythmic therapies.
  • To identify potential benefits and challenges associated with these drug combinations.

Main Methods:

  • Literature review of studies investigating combinations of sotalol and amiodarone with other antiarrhythmic drugs.
  • Analysis of electrophysiologic data and clinical outcomes related to drug combinations.
  • Evaluation of pharmacokinetic interactions, particularly for amiodarone.

Main Results:

  • Combining sotalol with type Ia drugs or amiodarone with low-dose beta-blockers may enhance efficacy.
  • Amiodarone combinations with type Ia/Ic drugs or beta-blockers can slow ventricular tachycardia rates.
  • Amiodarone exhibits extensive pharmacokinetic interactions, including induced hepatic metabolism, with uncertain physiological effects.
  • Sotalol is expected to have few pharmacokinetic interactions due to its absorption, protein binding, and excretion profile.

Conclusions:

  • Drug combinations with class III antiarrhythmics show promise for improved efficacy and management of ventricular tachycardia.
  • Amiodarone's pharmacokinetic profile presents significant interaction potential, requiring careful consideration.
  • Sotalol appears to have a favorable pharmacokinetic profile for combination therapy.
  • Further systematic investigation into these drug combinations is warranted.

Related Experiment Videos